12Suppliers
26Customers
1Debt Items
20Related Chains

Source-Backed Evidence Depth

Royalty Pharma plc (RPRX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

40Total relationships
4Distinct source URLs
14High confidence
0.756Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Royalty Pharma plc Suppliers

TickerNameConfidenceEvidence
RVMD Revolution Medicines, Inc. 92% Reciprocal relationship from RVMD graph: Pursuant to the Royalty Purchase Agreement, Royalty Pharma purchased from the Company the right to receive tiered revenue payments with respect to worldwide n…
RVMD Revolution Medicines, Inc. 92% In June 2025, Royalty Pharma (the “Company”) and Revolution Medicines announced a $2 billion funding agreement, consisting of a synthetic royalty of up to $1.25 billion on daraxonrasib and a senior s…
NERV Minerva Neurosciences, Inc. 90% Reciprocal relationship from NERV graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from NERV graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from NERV g…
NUVL Nuvalent, Inc. 90% Reciprocal relationship from NUVL graph: lue of the related party revenue share liability was $55.2 million and $17.9 million for the years ended December 31, 2025 and 2024, respectively. For the yea…
PRTC PureTech Health plc 90% Reciprocal relationship from PRTC graph: Upon closing, we received an upfront payment of $100.0 million from Royalty Pharma
PTCT PTC Therapeutics, Inc. 90% Reciprocal relationship from PTCT graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from PTCT graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from PTCT g…
DNLI Denali Therapeutics Inc. 72% Reciprocal relationship from DNLI graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from DNLI g…
JNJ Johnson & Johnson 72% Reciprocal relationship from JNJ graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from JNJ grap…
MRK Merck & Co., Inc. 72% Reciprocal relationship from MRK graph: n ADC and all remaining candidates achieve regulatory approval. In addition, Kelun-Biotech is eligible to receive tiered royalties ranging from a mid-single-di…
SWKH SWK Holdings Corp 72% Reciprocal relationship from SWKH graph: key personnel were to join or form a competitor, our business could similarly suffer a material adverse effect. In addition, we have very few employees, so th…
TEVJF Teva Pharmaceutical Industries Limited 72% Reciprocal relationship from TEVJF graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from TEVJF graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from TEVJ…
VRTX Vertex Pharmaceuticals Incorporated 72% Reciprocal relationship from VRTX graph: l expansions for our current medicines. We expect to continue to focus significant resources to expand and maintain reimbursement for our CF medicines, CASGEV…

Royalty Pharma plc Customers

TickerNameConfidenceEvidence
CYTK Cytokinetics, Incorporated 92% Reciprocal relationship from CYTK graph: We have entered into certain revenue participation right purchase agreements for omecamtiv mecarbil, aficamten, and CK-586 with affiliates of Royalty Pharma, …
DNLI Denali Therapeutics Inc. 90% Reciprocal relationship from DNLI graph: The information contained in Item 1.01 of the Form 8-K filed by Denali Therapeutics Inc. (the “Company”) on December 4, 2025 related to the synthetic royalty …
SNDX Syndax Pharmaceuticals, Inc. 90% Reciprocal relationship from SNDX graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from SNDX graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from SNDX g…
VERTEX VERTEX 90% Royalty payor that accounted for 36% of our total income and other revenues in 2024 and 2023
ARWR Arrowhead Pharmaceuticals, Inc. 85% Reciprocal relationship from ARWR graph: In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise pa…
ROCHE ROCHE 80% Royalty payor that accounted for 10% of our total income and other revenues in 2024
CYTK Cytokinetics, Incorporated 72% portion of the EPAs may be paid in cash as a tax advance to cover income tax obligations incurred by the beneficial owners of the RP Holdings Class C Special Interest. Mr. Legorreta granted ownership…
JNJ Johnson & Johnson 72% Reciprocal relationship from JNJ graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from JNJ grap…
JNJ Johnson & Johnson 72% . As a result of our significant scale and highly flexible business model, we believe that we are uniquely positioned to capitalize on multiple compounding growth drivers: an accelerating understandi…
NUVL Nuvalent, Inc. 72% Reciprocal relationship from NUVL graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from NUVL graph: d other current assets of $16.9 million. During the year ended December 31, …
RVMD Revolution Medicines, Inc. 72% STATEMENTS (UNAUDITED) 10. Non-Consolidated Affiliates We have equity investments in certain entities at a level that provide us with significant influence. We account for such investments as equity …
RVMD Revolution Medicines, Inc. 72% Reciprocal relationship from RVMD graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from RVMD graph: Reciprocal relationship from RPRX graph: STATEMENTS (UNAUDITED) 10. Non-Cons…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from SNYN…
SNYNF Sanofi 72% 1, 2024 and 2023 based on a discounted cash flow calculation using estimated risk-adjusted discount rates, which are Level 3 inputs. Our estimate of the risk adjusted discount rates could reasonably …
TBPH Theravance Biopharma, Inc. 72% . As a result of our significant scale and highly flexible business model, we believe that we are uniquely positioned to capitalize on multiple compounding growth drivers: an accelerating understandi…
TBPH Theravance Biopharma, Inc. 72% Reciprocal relationship from TBPH graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from TBPH graph: Reciprocal relationship from RPRX graph: . As a result of our significant sc…
APIJECT-HOLDINGS-INC APIJECT-HOLDINGS-INC 62% ing derivative instruments such as treasury rate lock contracts. Our policy is to use derivatives strategically to hedge existing and future interest rate exposure and to minimize volatility in cash …
CONTROLLED-FOREIGN-COMPANY CONTROLLED-FOREIGN-COMPANY 62% engaged in the conduct of a trade or business within the United States, and as such, we do not record a provision for U.S. income taxes with respect to effectively connected income for the years pres…
FOLLOWING-PFIZER-INC FOLLOWING-PFIZER-INC 62% ing derivative instruments such as treasury rate lock contracts. Our policy is to use derivatives strategically to hedge existing and future interest rate exposure and to minimize volatility in cash …
MA Mastercard Incorporated 62% Reciprocal relationship from MA graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from MA graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from MA graph: …
PABLO-LEGORRETA-RPM-I-LLC PABLO-LEGORRETA-RPM-I-LLC 62% MA PLC NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) Legal Proceedings We are a party to legal actions with respect to a variety of matters in the ordinary course of business. …
RP-HOLDINGS RP-HOLDINGS 62% idated affiliates: 1. Legacy SLP Interest. In connection with the Exchange Offer, we acquired an equity method investment from the Continuing Investors Partnerships in the form of a special limited p…
RP-MIP-HOLDINGS RP-MIP-HOLDINGS 62% MA PLC NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) Legal Proceedings We are a party to legal actions with respect to a variety of matters in the ordinary course of business. …
RP-MIP-HOLDINGS-LLC RP-MIP-HOLDINGS-LLC 62% terial changes to our significant accounting policies from our Annual Report on Form 10-K for the year ended December 31, 2025. 3. Internalization On January 10, 2025, we entered into an agreement (a…
RPM-ROYALTY-PHARMA-MANAGER-LLC RPM-ROYALTY-PHARMA-MANAGER-LLC 62% terial changes to our significant accounting policies from our Annual Report on Form 10-K for the year ended December 31, 2025. 3. Internalization On January 10, 2025, we entered into an agreement (a…
TEVA Teva Pharmaceutical Industries Limited 62% Reciprocal relationship from TEVA graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from TEVA graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from TEVA g…

Royalty Pharma plc Debt Obligations

InstrumentDescriptionConfidenceEvidence
RPRX-DEBT Debt stack $9.0B 90% Market cache reports total debt of $9.0B.

Royalty Pharma plc Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Royalty Pharma plc.

Royalty Pharma plc Ownership

HolderNameConfidenceEvidence
RPRX-OWNER-MORGAN-STANLEY MORGAN STANLEY 90% 13F overlay lists MORGAN STANLEY as top holder; 590 tracked holders.

Royalty Pharma plc Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
DSGN Design Therapeutics, Inc. 100.00 2
DYN Dyne Therapeutics, Inc. 100.00 2
BNRG Brenmiller Energy Ltd 100.00 2
CCEP Coca-Cola Europacific Partners PLC 100.00 2
AZN AstraZeneca PLC 100.00 2
CSTE Caesarstone Ltd. 100.00 2
CYTK Cytokinetics, Incorporated 100.00 1 ['customer']
BNR Burning Rock Biotech Limited 100.00 2
ANIK Anika Therapeutics, Inc. 100.00 2
AORT Artivion, Inc. 100.00 2
AVBP ArriVent BioPharma, Inc. 100.00 2
BLLN BillionToOne, Inc. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
BLRX BioLineRx Ltd. 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
DBVTF DBV TECHNOLOGIES 100.00 2
🔐
RPRX
Unlock RPRX Supply Chain Data
Verified relationships include:
RVMDRevolution Medicines, Inc.Supplier92%
RVMDRevolution Medicines, Inc.Supplier92%
CYTKCytokinetics, IncorporatedCustomer92%
DNLIDenali Therapeutics Inc.Customer90%
+36 more relationships locked
Subscribe, View plans →